• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.

作者信息

Lulla Premal D, Brammer Jonathan E, Bandeali Salman, Lynch Garret R

机构信息

Department of Medicine, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77004, USA.

出版信息

J Gastrointest Cancer. 2013 Mar;44(1):98-101. doi: 10.1007/s12029-012-9438-6.

DOI:10.1007/s12029-012-9438-6
PMID:23054578
Abstract
摘要

相似文献

1
Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.单药索拉非尼治疗转移性肝细胞癌的持续完全缓解
J Gastrointest Cancer. 2013 Mar;44(1):98-101. doi: 10.1007/s12029-012-9438-6.
2
Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.索拉非尼治疗晚期肝细胞癌实现持续完全缓解
J Dig Dis. 2015 Sep;16(9):537-40. doi: 10.1111/1751-2980.12270.
3
Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.一名老年肝癌患者对全剂量索拉非尼治疗的完全缓解：病例报告
J Gastrointest Cancer. 2015 Dec;46(4):430-3. doi: 10.1007/s12029-015-9720-5.
4
Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.帕博利珠单抗联合索拉非尼治疗转移性肝细胞癌完全缓解：一例报告
Am J Gastroenterol. 2017 Apr;112(4):659-660. doi: 10.1038/ajg.2017.1.
5
Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.索拉非尼对一名复发性肝细胞癌患者的完全缓解。
World J Gastroenterol. 2014 Oct 21;20(39):14505-9. doi: 10.3748/wjg.v20.i39.14505.
6
Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.中性粒细胞与淋巴细胞比值在接受索拉非尼治疗的晚期肝细胞癌患者中的预测作用
Asian Pac J Cancer Prev. 2014;15(2):1063. doi: 10.7314/apjcp.2014.15.2.1063.
7
Education and imaging: Hepatobiliary and pancreatic: Volume-perfusion CT for monitoring therapy for hepatocellular carcinoma.教育与影像学：肝胆胰：用于监测肝细胞癌治疗的容积灌注CT
J Gastroenterol Hepatol. 2013 Mar;28(3):588. doi: 10.1111/jgh.12094.
8
Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.多结节性肝癌患者索拉非尼剂量减少后的部分缓解及心血管功能恢复
J Gastrointest Cancer. 2012 Sep;43 Suppl 1:S89-92. doi: 10.1007/s12029-011-9328-3.
9
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.索拉非尼治疗晚期肝细胞癌后的完全放射学缓解
Tunis Med. 2015 Jun;93(6):350-2.
10
Long-term treatment of hepatocellular carcinoma with sorafenib.索拉非尼对肝细胞癌的长期治疗
Infez Med. 2013 Jun;21(2):167-8.

引用本文的文献

1
Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment.经20天索拉非尼治疗治愈的伴有远处转移的肝细胞癌
Case Rep Gastroenterol. 2021 Jul 8;15(2):610-615. doi: 10.1159/000514529. eCollection 2021 May-Aug.
2
Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review.联合治疗对伴有右心房和肺转移的肝细胞癌的完全缓解（自然杀伤细胞的一种可能治疗效果）：一例报告及文献综述
Medicine (Baltimore). 2018 Oct;97(42):e12866. doi: 10.1097/MD.0000000000012866.
3

本文引用的文献

1
Complete response for advanced liver cancer during sorafenib therapy: case report.索拉非尼治疗期间晚期肝癌完全缓解：病例报告。
BMC Gastroenterol. 2011 Jan 17;11:4. doi: 10.1186/1471-230X-11-4.
2
Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.索拉非尼低剂量治疗不可切除肝细胞癌完全缓解 1 例报告。
Target Oncol. 2010 Mar;5(1):59-63. doi: 10.1007/s11523-010-0133-x. Epub 2010 Mar 23.
3
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
索拉非尼实现晚期肝细胞癌完全缓解的病例分析
Eur J Med Res. 2015 Feb 4;20(1):12. doi: 10.1186/s40001-015-0085-9.
索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性：一项III期随机、双盲、安慰剂对照试验。
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
4
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.铁沉积症患者索拉非尼治疗转移性肝细胞癌的完全临床缓解：病例报告。
J Hematol Oncol. 2008 Oct 17;1:18. doi: 10.1186/1756-8722-1-18.
5
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
6
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.索拉非尼阻断RAF/MEK/ERK通路，抑制肿瘤血管生成，并在肝癌模型PLC/PRF/5中诱导肿瘤细胞凋亡。
Cancer Res. 2006 Dec 15;66(24):11851-8. doi: 10.1158/0008-5472.CAN-06-1377.
7
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.索拉非尼治疗晚期肝细胞癌患者的II期研究。
J Clin Oncol. 2006 Sep 10;24(26):4293-300. doi: 10.1200/JCO.2005.01.3441. Epub 2006 Aug 14.
8
Global cancer statistics, 2002.2002年全球癌症统计数据。
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. doi: 10.3322/canjclin.55.2.74.
9
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.BAY 43 - 9006具有广谱口服抗肿瘤活性，作用于参与肿瘤进展和血管生成的RAF/MEK/ERK信号通路及受体酪氨酸激酶。
Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443.
10
Hepatocellular carcinoma.肝细胞癌
Lancet. 2003 Dec 6;362(9399):1907-17. doi: 10.1016/S0140-6736(03)14964-1.